Elcelyx Therapeutics is developing ultra-safe products for weight management and obesity-related metabolic disorders based on the science of nutrient sensing. The Elcelyx first-in-class product candidates, Lovidia(TM) and NewMet(TM), are Gut Sensory Modulators backed by rigorous science and clinical data demonstrating their ability to rapidly reduce weight and improve glucose metabolism without systemic side effects, respectively. The products represent reduced-risk, near-term blockbuster opportunities in weight management and Type 2 diabetes with longer-term opportunities in obesity and prediabetes.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/13/12 | $4,000,000 | Series B |
Morgenthaler Technology Partners | undisclosed |
| 02/14/13 | $20,000,000 | Series C |
GSM Fund Morgenthaler Technology Partners | undisclosed |
| 10/01/15 | $40,000,000 | Series E |
Clough Capital Partners GSM Fund Morgenthaler Sailing Capital Technology Partners | undisclosed |
